Sun Pharma stock trades at INR 1,760.00, 14.0 percent below its 52-week high

Published on 10/09/2026 at 15:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q1 fiscal 2027 revenue hit INR 153.0 billion, up 10.10 percent. Sun Pharma stock costs INR 1,760.00 on October 9, 2026 after INR 1,759.80.

Key points in brief

Sun Pharma stock was last at INR 1,760.00 on NSE on October 9, 2026 at 3:25 p.m. IST, up 0.01 percent versus INR 1,759.80.
The stock stood 14.02 percent below its 52-week high of INR 2,046.90 recorded on October 8, 2026.
Q1 fiscal 2027 revenue reached INR 153.0 billion, up 10.50 percent year over year, while net profit rose 27.00 percent to INR 28.95 billion.
Investing.com listed a 12-month average analyst target of INR 2,175.59 from 32 analysts.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma stock (INE044A01036) was last at INR 1,760.00 on NSE on October 9, 2026 at 3:25 p.m. IST, up 0.01 percent versus INR 1,759.80. The price stood 14.02 percent below the 52-week high of INR 2,046.90 recorded on October 8, 2026, according to The Economic Times.

Price remains below yearly high

The October 9 quote places Sun Pharma 11.12 percent above the 52-week low of INR 1,583.70 reported for the NSE on October 8. The same market listing showed a prior close of INR 1,781.00 for October 8, making the current quote INR 21.00 lower than that level.

The stock's 52-week span from INR 1,583.70 to INR 2,046.90 gives investors a wide valuation frame. The current price is closer to the lower end of that span than to the yearly high, while the day itself shows only a 0.01 percent gain against the prior close.

Latest quarter sets baseline

Sun Pharma reported Q1 fiscal 2027 revenue of INR 153.0 billion, up 10.50 percent year over year, and net profit of INR 28.95 billion, up 27.00 percent, according to ALFA Finder in its October 6, 2026 filing summary. That combination puts profit growth ahead of revenue growth for the reported quarter.

ALFA Finder also identified Sun Pharma's Q1 fiscal 2027 earnings per share at INR 12.10 and its EBITDA margin at 28.90 percent. The figures frame the stock's current market value through operating expansion rather than price movement alone.

Analyst target remains higher

Investing.com listed a 12-month average target of INR 2,175.59 from 32 analysts as of October 9, 2026. That target lies 23.61 percent above the NSE price of INR 1,760.00, using the same Indian rupee quotation.

The contrast is clear: Q1 fiscal 2027 net profit rose 27.00 percent, while the current price remains 14.02 percent below its 52-week high. For investors, the next market question is whether earnings growth can narrow that gap over time.

Comparison with peers

Sun Pharma (NSE, INR): plus 0.01 percent, ,

Cipla (NSE, INR): , ,

Dr. Reddy's Laboratories (NSE, INR): , ,

Sun Pharma market snapshot

Sun Pharma was last at INR 1,760.00 on NSE on October 9, 2026 at 3:25 p.m. IST, up 0.01 percent versus the NSE prior close of INR 1,759.80. The further course of trading is shown by the continuously updated real-time quote of Sun Pharma stock.